ABSI
Absci Corp
NASDAQ: ABSI · HEALTHCARE · BIOTECHNOLOGY
$4.71
-3.09% today
Updated 2026-04-29
Market cap
$732.16M
P/E ratio
—
P/S ratio
261.48x
EPS (TTM)
$-0.84
Dividend yield
—
52W range
$2 – $5
Volume
4.1M
Absci Corp (ABSI) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.06M | $4.78M | $4.78M | $5.75M | $5.72M | $4.53M | $2.80M |
| Revenue growth (YoY) | — | +132.0% | +0.0% | +20.2% | -0.5% | -20.7% | -38.2% |
| Cost of revenue | $4.31M | $11.45M | $44.59M | $58.91M | $47.57M | $62.46M | $11.74M |
| Gross profit | $2.06M | $-6.67M | $-39.80M | $-53.16M | $-41.85M | $-57.92M | $-8.94M |
| Gross margin | 100.0% | -139.5% | -832.4% | -925.0% | -731.9% | -1277.6% | -319.4% |
| R&D | $4.31M | $11.45M | $44.59M | $58.91M | $48.07M | $63.86M | $81.42M |
| SG&A | $3.52M | $5.50M | $28.78M | $40.55M | $36.26M | $36.17M | $35.06M |
| Operating income | $-6.26M | $-13.30M | $-75.24M | $-106.75M | $-115.52M | $-108.89M | $-124.72M |
| Operating margin | -304.1% | -278.3% | -1573.4% | -1857.5% | -2020.2% | -2401.6% | -4454.2% |
| EBITDA | $-5.83M | $-12.59M | $-67.68M | $-93.71M | $-79.68M | $-94.10M | $-112.98M |
| EBITDA margin | -282.8% | -263.3% | -1415.4% | -1630.6% | -1393.5% | -2075.4% | -4034.9% |
| EBIT | $-6.32M | $-13.72M | $-74.34M | $-106.75M | $-93.68M | $-107.49M | $-124.72M |
| Interest expense | $268000.00 | $634000.00 | $3.43M | $972000.00 | $1.01M | $565000.00 | $209000.00 |
| Income tax | $217000.00 | $216000.00 | $-8.90M | $-461000.00 | $100000.00 | $70000.00 | — |
| Effective tax rate | -3.4% | -1.5% | 8.1% | 0.4% | -0.1% | -0.1% | 0.0% |
| Net income | $-6.58M | $-14.35M | $-100.96M | $-104.90M | $-110.57M | $-103.11M | $-115.18M |
| Net income growth (YoY) | — | -118.0% | -603.4% | -3.9% | -5.4% | +6.7% | -11.7% |
| Profit margin | -319.6% | -300.3% | -2111.3% | -1825.4% | -1933.6% | -2274.1% | -4113.7% |